medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2019, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2019; 64 (2)

Evaluation of the recovery of the neuromuscular block by rocuronio at a dose calculated by lean weight versus dose calculated by ideal weight

Castellano RMP, Ruiz VRE, Delgado CMM

Language: Spanish
References: 15
Page: 93-97
PDF size: 205.66 Kb.


ABSTRACT

Introduction: There are currently doubts about how to dose neuromuscular relaxants in overweight patients. It is recommended to dose rocuronium at ideal weight, but, since this type of dosage does not consider the percentage of fatty tissue, it represents an increase in the risk of residual neuromuscular paralysis. Objective: To compare the recovery of neuromuscular block with Rocuronium when administered based on lean weight compared to idea weight. Material and methods: A double-blind, controlled clinical trial was applied to 100 patients who were randomized into two groups (group M and group I) to administer rocuronium with ED95 (600 µg/kg) calculated at lean weight and ideal weight. TOF record: basal (t0), at the end of the rocuronium injection (t1), time to reach the maximum suppression of T1 (t2), time to reach 25% of T1 (t3) and time to recovery of 75 and 90% of T1 (t4 and t5). Results: No significant differences were found in the general conditions, in the group M a longer latency time was observed and a complete clinical recovery (› 90% T1) faster statistically significant (p ‹ 0.05). Conclusions: The recovery of the neuromuscular block after the administration of rocuronium calculated at lean weight is significantly faster compared to the use of ideal weight, thus generating a reduction in the risk of residual neuromuscular relaxation.


REFERENCES

  1. Monteverde M, Novak B. Obesidad y esperanza de vida en México. Poblac Salud Mesoam. 2008; 6 (1). pii: 4.

  2. Organización Mundial de la Salud. Obesidad y sobrepeso. Centro de prensa, 2016. Disponible en: http://www.who.int/mediacentre/factsheets/fs311/es/

  3. Organización para la Cooperación y el Desarrollo Económicos (OEDC). Obesity Update 2017.

  4. García-Arreola DAP, Alcántara-Morales MA. Obesidad: alteraciones fisiopatológicas y su repercusión anestésica. Rev Mex Anest. 2014; 37 (S1): S198-S206.

  5. Sosa F, Tomas F, Urioste G, Xavier S, Bouchacourt JP. Evaluación del rocuronio en la práctica clínica. Anest Analg Reanim. 2014; 27 (2): 4.

  6. Navarro-Vargas JR, Valero-Bernal JF. La obesidad y sus implicaciones desde la perspectiva de la anestesiología. Rev Cuba Anestesiol Reanim. 2014; 13 (2): 156-167.

  7. Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010; 105 Suppl 1: i16-i23.

  8. Fujimoto M, Tanahira C, Nishi M, Yamamoto T. In non-obese patients, duration of action of rocuronium is directly correlated with body mass index. Can J Anaesth. 2013; 60 (6): 552-556.

  9. Farhan H, Moreno-Duarte I, McLean D, Eikermann M. Residual paralysis: does it influence outcome after ambulatory surgery? Curr Anesthesiol Rep. 2014; 4 (4): 290-302.

  10. Castagnoli A, Adversi M, Innocenti G, Di Nino GF, Melotti RM. Post-operative residual curarization (PORC): a big issue for patients’ safety. Risk management for the future-theory and cases. Editorial Dr Jan Emblemsvåg; 2012. pp. 117-138.

  11. Thilen SR, Bhananker SM. Qualitative neuromuscular monitoring: how to optimize the use of a peripheral nerve stimulator to reduce the risk of residual neuromuscular blockade. Curr Anesthesiol Rep. 2016; 6: 164-169.

  12. Fabregat-López J, Candia-Arana CA, Castillo-Monzón CG. Neuromuscular monitoring and its importance in neuromuscular blockade. Rev Colomb Anestesiol. 2012; 40 (4): 293-303.

  13. Jing Z, Muheremu A, Liu P, Hu X, Binjiang Z. Administration of rocuronium based on real body weight versus fat-free mass in patients with lymphedema. J Int Med Res. 2017; 45 (6): 2072-2077.

  14. Sakızcı-Uyar B, Çelik S, Postacı A, Bayraktar Y, Dikmen B, Özkoçak-Turan I et al. Comparison of the effect of rocuronium dosing based on corrected or lean body weight on rapid sequence induction and neuromuscular blockade duration in obese female patients. Saudi Med J. 2016; 37 (1): 60-65.

  15. Ojeda DD, Gazabatt SF, Bustamante BR, Burgos WA, Cisternas MP. Rocuronio en obesos: ¿debe dosificarse por peso real o peso ideal? Rev Chil Anest. 2014; 43: 16-22.




2020     |     www.medigraphic.com